TD Cowen Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces Price Target of $75
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with an Outperform rating and set a price target of $75 for the company's stock.
December 11, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies receives an Outperform rating from TD Cowen with a price target of $75, indicating a positive outlook on the stock.
The initiation of coverage by TD Cowen with an Outperform rating typically suggests a positive forecast for the stock's performance. The price target of $75 implies a significant upside potential from the current trading price, which may attract investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100